



Universiteit
Leiden
The Netherlands

Metabolomics study of blood vessels-on-chip model

Kallakkudi Pandian, K.

Citation

Kallakkudi Pandian, K. (2025, March 26). *Metabolomics study of blood vessels-on-chip model*. Retrieved from <https://hdl.handle.net/1887/4209144>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4209144>

Note: To cite this publication please use the final published version (if applicable).



Chapter 2

Tracer-based metabolomics for profiling nitric oxide metabolites in a 3D microvessels-on-chip model

**Kanchana Pandian, Luojiao Huang, Abidemi Junaid, Amy Harms, Anton Jan
van Zonneveld* and Thomas Hankemeier***

**These authors are co-corresponding authors*

The FASEB Journal. 2024;38(16):370005. doi: 10.1096/fj.202400553R

Abstract

Endothelial dysfunction, prevalent in cardiovascular diseases (CVDs) and linked to conditions like diabetes, hypertension, obesity, renal failure, or hypercholesterolemia, is characterized by diminished nitric oxide (NO) bioavailability—a key signaling molecule for vascular homeostasis. Current two-dimensional (2D) *in vitro* studies on NO synthesis by endothelial cells (ECs) lack the crucial laminar shear stress, a vital factor in modulating the NO-generating enzyme, endothelial nitric oxide synthase (eNOS), under physiological conditions.

Here we developed a tracer-based metabolomics approach to measure NO-specific metabolites with mass spectrometry (MS) and show the impact of fluid flow on metabolic parameters associated with NO synthesis using 2D and 3D platforms. Specifically, we tracked the conversion of stable-isotope labeled NO substrate L-Arginine to L-Citrulline and L-Ornithine to determine eNOS activity.

We demonstrated clear responses in human coronary artery endothelial cells (HCAECs) cultured with $^{13}\text{C}_6, ^{15}\text{N}_4$ -L-Arginine, treated with eNOS stimulator, eNOS inhibitor, and arginase inhibitor. Analysis of downstream metabolites, $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline and $^{13}\text{C}_5, ^{15}\text{N}_2$ L-Ornithine, revealed distinct outcomes. Additionally, we evaluated the NO metabolic status in static 2D culture and 3D micro vessel models with bidirectional and unidirectional fluid flow. Our 3D model exhibited significant effects, particularly in microvessels exposed to the eNOS stimulator, as indicated by the $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline / $^{13}\text{C}_5, ^{15}\text{N}_2$ L-Ornithine ratio, compared to the 2D culture.

The obtained results indicate that the 2D static culture mimics an endothelial dysfunction status, while the 3D model with a unidirectional fluid flow provides a more representative physiological environment that provides a better model to study endothelial dysfunction.

Key words

Nitric Oxide metabolites, eNOS, endothelial dysfunction, 3D micro vessel model, shear stress

Introduction

Nitric Oxide is an essential diatomic molecule that is generated by eNOS/NOS3 and that exerts multiple key roles in vascular homeostasis, including vasodilation and inflammation. The eNOS enzyme can be activated by multiple physiological (oxygen and shear stress) [1] or humoral (bradykinin and insulin) cues that drive diverse phosphorylation events on multiple sites such as serine 114, 615, 633, 1177, 1179 and threonine 495 in the oxygenase and reductase domains of the protein [2]. When released from the endothelium, NO diffuses into vascular stromal cells such as pericytes or smooth muscle cells to promote vascular relaxation through the stimulation of cyclic guanosine monophosphate (cGMP synthesis by soluble guanylyl cyclase [3–5].

Dysregulation of NO signaling pathways is associated with pathophysiological conditions such as endothelial dysfunction, a main driver for atherogenesis and cardio-metabolic disorders [6–8]. In endothelial dysfunction, reduced availability of NO converts the endothelial cell phenotype to a pro-inflammatory state with increased oxidative stress and a loss of vasodilatory capacity [9,10]. At the molecular level, multiple factors have been reported to contribute to the loss of NO generation in endothelial dysfunction, including a deficiency in the substrate L-arginine or co-factors such as flow-mediated dilation (FMD), nicotinamide adenine dinucleotide phosphate (NADPH), or tetrahydrobiopterin (BH₄). For instance, when BH₄ is converted to BH₂ (7,8-dihydrobiopterin) in an oxidative environment, the eNOS enzyme gets uncoupled from the cofactor leading to the generation of superoxide rather than NO [11–16].

At the physiological level, it is well established that fluid shear stress enhances the activity of eNOS [17,18]. Endothelial cells detect changes in local hemodynamics through mechanosensors located on the luminal side of the membrane, in the focal adhesions in the abluminal side, and in the cell-cell junctional complexes. When exposed to laminar shear stress, endothelial cells activate and mobilize Ca²⁺ from intercellular stores. This mobilization leads to the formation of Ca²⁺/calmodulin complexes, which then bind and activate the eNOS enzyme [19]. Furthermore, fluid shear stress induces the eNOS activation through the tyrosine phosphorylation of PECAM-1 (platelet endothelial cell adhesion molecule-1). This process enhances the phosphorylation of eNOS at Ser¹¹⁷⁷ and

Akt Ser⁴⁷³ residues. In contrast, lower levels of activation are observed in static conditions in human umbilical cord vein endothelial cells (HUVECs) [20]. Under laminar flow conditions, endothelial cells exhibit an atheroprotective phenotype. However, when laminar flow is disturbed or absent, the cells shift to an inflamed phenotype characterized by the activation of NF- κ B [21]. This shift in phenotype can contribute to thermogenesis, inflammation, atherosclerosis [22,23] and obstructive pulmonary disease [24].

Given the crucial role of shear stress in accurately modeling physiological endothelial responses to risk factors, it is essential for *in vitro* models to incorporate environmental cues such as laminar shear. This necessity is underscored by studies indicating that static endothelial cell-culture models exhibit a proinflammatory phenotype [25], display features of complement-mediated injury [26] and show impaired NO production [27,28]. When it comes to developing 3D models, microfluidics emerges as an optimal technology for introducing flow into a 3D microvascular structure [25,29]. The accurate measurement of NO poses a challenge due to its strong reactivity, short half-life, and low physiological concentrations. Traditional techniques such as the Griess assay, chemiluminescence, and amperometric NO sensor readings faces limitations in accuracy and sensitivity [30–34]. However, measuring stable metabolites involved in NO production provides a viable approach to quantify NO, even at the low abundance in microfluidic cell models.

In particular, tracer-based metabolomics stands out as the gold standard method. This approach utilizes stable isotope-labelled precursors to trace complex pathways by following the labeled atom(s) to downstream metabolites [35,36]. This technique, applied to enzymatic reactions involved in NO production [37–42] enhances accuracy and sensitivity, overcoming the challenges associated with traditional NO measurement methods. To evaluate the influence of adverse metabolic and inflammatory plasma factors on eNOS activity in both 2D and 3D endothelial cell models, we aimed to employ our tracer-based metabolomics strategy. In our study, we used ¹³C₆,¹⁵N₄ L-arginine as a substrate for eNOS, and traced its downstream metabolites ¹³C₆,¹⁵N₃ L-citrulline (a co-

product of NO production produced at equal molar amounts) and $^{13}\text{C}_5$, $^{15}\text{N}_2$ L-ornithine (contributing to citrulline production).

To assess these L-arginine downstream metabolites, we employed an optimized AccQ-Tag amino acid derivatization sample preparation method coupled with a targeted LCMS (liquid chromatography and Mass spectrometry) approach. To validate the accuracy of our method in reflecting endothelial cell biochemistry, we measured changes in metabolite flux in cell models treated with stimulatory and inhibitory compounds for eNOS and arginase. Furthermore, we investigated the impact of unidirectional fluid flow on metabolic parameters associated with NO synthesis. This involved a comparison between a three-dimensional (3D) microvessels-on chip model with controlled fluid flow [29,43], and a 2D static cell culture model. The results obtained highlight the suitability of the LCMS method for measuring low-volume and low-abundance NO downstream metabolites. Notably, the 3D model reveals significant changes upon VEGF stimulation compared to the control situation, as evidenced by changes in Citrulline+9/Ornithine+7. In contrast, static 2D culture lacks significant changes upon VEGF stimulation, indicating a non-regulated eNOS and arginase pathway, reflecting an endothelial dysfunction condition. Furthermore, under flow conditions, there are elevated levels of mechanosensitive gene expression compared to static, low shear and bidirectional flow statuses. These results underscore the potential importance of shear stress and NO metabolite levels in influencing endothelial responses and gene expression patterns.

Material and Methods

Chemicals and reagents

Vascular Endothelial Growth Factor (VEGF) (PeproTech, Netherlands), L-NAME (Abcam, Netherlands), BEC (Sigma Aldrich, Netherlands), BH4 (Merck, Netherlands). RPMI SILAC - medium deficient in Arginine was obtained from (Thermofisher, Netherlands). Isotope labelled L-Arginine was obtained from (CORTECNET, Netherlands). Cells were grown under 5% CO₂, with 95% atmospheric air. Oxygen

experiments were performed in a Panasonic 97 oxygen incubator. DAF-2D was obtained from (Abcam, Netherlands).

Cell culture and experimental procedures

Human coronary artery endothelial cells (HCAECs) (PromoCell, Netherlands) were resuspended in 10 ml fresh EGM MV2 medium with supplements (PromoCell, Netherlands) and cultured in T75 flasks (Nunc Easyflask, Sigma, Netherlands). Cell cultures were maintained at 37 °C with 5% CO₂ and media was refreshed three times a week. Cells were detached at 85% confluence with 0.25 % Trypsin EDTA (Lonza, Netherlands) and cell pellets were collected by centrifugation at 300g for 5 minutes.

Commercially available RPMI SILAC medium was used, a formulation specifically designed for stable isotope labeling with amino acids in cell culture (SILAC). These medium lacks arginine, allowing for the incorporation of isotopically labeled L-arginine (¹³C₆ ¹⁵N₄-L-arginine) at a concentration of 150 μM into the cells. Following treatment, we measured the downstream labeled metabolites in the cells. For 2D culture experiments, the collected cell pellets were suspended in a fresh medium to a concentration of 7 x 10⁵ cells/ml and cultured in a 48 well plate for 48 hours. The following day, cells were serum starved with 1% FCS in basal EGM2 (Bioconnect, Netherlands) medium and incubated overnight. To synchronize or equilibrate the cell cycle, we treated cells with Krebs buffer solution, pH 7.4 (Thermo fisher Scientific, Netherlands) for 1 hour before the start of each experiment. Subsequently the cells were incubated for 12 hours with RPMI SILAC (ThermoFisher Scientific, Netherlands) supplemented with 150μM ¹³C₆, ¹⁵N₄-L-arginine (CORTECNET, Netherlands), 10 μM of (6R)-5,6,7,8,-Tetrahydrobiopterin dihydrochloride (BH₄) and 1% FCS (Thermofisher Scientific, Netherlands) in the presence of 100ng/ml VEGF, 1mM L-NAME or 100μM BEC separate or in the indicated combinations. The medium and cells were collected separately and snap frozen in liquid nitrogen and stored in -80°C for LCMS analysis.

For 3D cultures, we used a modified chip design 2-lane rerouted OrganoPlate (MIMETAS, Netherlands) that was adapted to attach a microfluidic pump to apply fluid flow and a normal 2-lane OrganoPlate to apply bidirectional flow. After seeding HCAECs

cells into the 3D microvessels, they were cultured for 3-4 days with media refreshed every other day. Similar to the 2D culture, once the cells formed a micro vessel, the following day, cells were serum starved with 1% FCS in basal EGM2 medium and incubated overnight. To synchronize or equilibrate the cell cycle, we treated cells with Krebs buffer solution, pH 7.4 for 1 hour before the start of each experiment. Subsequently, the cells were incubated for 12 hours with RPMI SILAC supplemented with 150 μ M 13C6, 15N4-L-arginine, 10 μ M of BH4 and 1% FCS in the presence of 100ng/ml VEGF, 1mM L-NAME or 100 μ M BEC separate or in the indicated combinations. The medium and cells were collected separately and snap frozen in liquid nitrogen and stored in -80°C for LCMS analysis

The approximate cell count in each 2D plate well is in the range of $7 - 8 \times 10^3$ and in the 3D OrganoPlate the approximate cell count is in the range $9 \times 10^3 - 1 \times 10^4$ cells/chip (with 96 chips per OrganoPlate).

Immunofluorescence microscopy

HCAECs were fixed using 4% paraformaldehyde (PFA) in HBSS+ for 10 min at room temperature. The fixative was aspirated, and the cells were rinsed once with HBSS+. The cells were permeabilized for 2 min with 0.2% Triton X-100 in HBSS+ and washed with HBSS+. Permeabilization was followed by blocking cells using 5% BSA in HBSS+ for 30 min and incubated with the primary antibody solution - Mouse anti-human CD144 (1:150) (BD Biosciences, USA) for overnight at 4°C. The cells were washed with HBSS+, followed by a one-hour incubation with Hoechst (1:2000) (Invitrogen, USA), rhodamine phalloidin (1:200) (Sigma-Aldrich, The Netherlands) and the secondary antibody solution, containing Alexa Fluor 488-conjugated goat anti-mouse (1:250) (ThermoFisher, USA). The cells were washed three times with HBSS+. High-quality images of the stained cells were acquired using a high-content confocal microscope (Molecular Devices, ImageXpress Micro Confocal).

Sample preparation for LC-MS

Samples were analyzed using a method based on an amine profiling platform that employed an AccQ-Tag derivatization strategy, adapted from the protocol provided by Waters [44]. The cell-treated media and cell lysates (10 μ L) were thawed on ice. For deproteination, water (5 μ L), Tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) (10 μ L), and absolute methanol (75 μ L) were added. Quality control (QC) samples were generated by pooling equal volumes of all cell media and cell lysate samples, and 10 μ L of this pool underwent the same process as individual samples. After centrifugation at 13,200 rpm for 10 minutes, the supernatant was transferred to a fresh Eppendorf tube and dried under a speed vacuum. The dried residue was reconstituted in borate buffer – pH 9 (10 μ L) vortexed for 10s and treated with 2.5 μ L of AccQ-TagAQC derivatization reagent (Waters, Waters B.V. Art. No. 186003836, The Netherlands). The samples were then kept at 55°C for 30 minutes in a shaker (Incubating microplate shaker, VWR, The Netherlands), 20% of formic acid (5 μ L) was added for neutralization. After a quick vortex, each sample was transferred to a deactivated auto sampler vial for LC-MS injection.

Instrumentation and LC-MS acquisition

Three μ L of sample solution was injected onto a UPLC Class I (Acquity, Waters Chromatography Europe BV, Etten-Leur, The Netherlands) system with an AccQ-Tag Ultra C18 Column (1.7 μ m, 100 x 2.1 mm, Waters, Ireland) coupled to a Sciex QTRAP® 6500 mass spectrometer [44]. For liquid chromatography (LC) separation, mobile phase A consisted of 0.1% formic acid in water. Mobile phase B consisted of 0.1% formic acid in acetonitrile. The flow rate used was 0.7 mL/min and the starting gradient condition was 99.8% A for 0.5 min, changing linearly to 90% A over the next 5.50 min, 80% A over 7.50 min, 40% A at 8.00 min, 5.0% A at 9.00 min, after which the solvent composition returned to 99.8% A over next 9.10 min and ends up with 99.8 % A and 0.2% B over in next 11.00 min. Mass spectrometry experiments were carried out on a SCIEX QTRAP 6500. The ESI source parameters were as follows (positive ion mode): Spray voltage \pm 5.5kV, capillary temperature 350°C, sheath gas 60 psi, auxillary gas 70 psi, curtain gas 30 psi. Data acquisition was performed in scheduled multiple reaction monitoring mode

targeting compounds with different labeling statuses. Q1 and Q3 resolutions for all transitions were set at unit resolution (0.7 amu fwhm) after testing with labeled cell samples. This setting was selective enough to reduce interferences from adjacent ions peaks. The compound list with target m/z for parent and product ions is shown in **Supplementary Table 1**. Raw LC-MS/MS data was processed with AB Sciex PeakView™ 2.0 and MultiQuant™ 3.0.1 software for targeted metabolite peak identification and integration. Metabolite isotopologue levels were quantified using the corresponding peak areas.

Microfluidic pump setup

HCAECs were seeded into an OrganoPlate (similar protocol mentioned in the above section) that was specially designed for controlled perfusion using a pump attachment. The pump is made of stainless steel and the tube connections for the fluid transfer from the inlet and outlet of the chips are made of silicone. For controlled rotation, a small motor is operated with the help of LabVIEW solutions software. This software allows the control of fluid flow rate and related shear stress (dyne/cm^2), use of portal connections, motor position and value. Typically, shear stress was applied for 12 hours for metabolic readouts and 12 and 24 hours for gene expression studies to condition the cells.

Validation of eNOS activity using DAF-2DA

HCAECs were cultured in a 48 well plate with $7-8 \times 10^3$ cells/ well suspended in a fresh EGM MV2 medium with supplements. Upon 80% confluence, the cells were starved with 1% FCS in EGM basal medium for 17 hours at 37°C with 5% CO₂. Next the cells were treated with Krebs buffer solution for 1 hour at 37°C. After two washes of PBS, 5μM of DAF-2DA stain (Abcam, Netherlands) was added and the cells were incubated for 1 hour at 37°C and then washed twice with PBS. The cells were treated with VEGF, L-NAME, BEC and only the working solution (basal EGM2 media with 1% FCS and 10μM BH₄) separately and incubated for 10-12 hours as described before. The cells were washed

twice with PBS and imaged in EVOS CO₂ incubator build fluorescent microscope with maximum excitation: 491nm and maximum emission: 513nm. The fluorescence intensities were measured by choosing ten random individual cells and grey scale intensity was analyzed using imageJ software to correlate with citrulline level.

Quantitative reverse transcription polymerase chain reaction (RT-PCR)

To perform RT-PCR, cells from 2D wells and OrganoPlate chips were collected by adding 100µL of RLT buffer (QIAGEN, Netherlands); after 60s of incubation at RT the lysates were collected, and RNA was extracted using Qiagen's RNeasy kit and Buffer RLT lysis buffer based on the manufacturer's recommendations. Next, to enable analysis of gene expression at low concentrations due to low cell counts, the lysate of eight microvessels from 3D cell culture models and eight well samples from 2D- 48 well plate was combined to make one sample. Reverse transcription-mediated cDNA synthesis was carried out using random and oligo(dT) primers (Bio-Rad, Netherlands) in accordance with the manufacturer's instructions using 200 ng of total RNA. For the qRT-PCR analysis, SYBR Select (Invitrogen) and a Biorad CFX384 were utilized. Krüppel-like transcription Factor2 (Klf2) (sense), CTACACCAAGAGTTCGCATCTG; Klf2 (antisense), AGCACGAACCTTGCCCATCA; 18S rRNA (sense), GGATGTAAAGGATGGAAAATACA; 18S rRNA (antisense), TCCAGGTCTTCACGGAGCTTGTT were the target genes whose primer sequences were employed. Expression levels were standardized to 18S rRNA and quantified using the comparative cycle threshold ($\Delta\Delta C_t$) method.

Statistical analysis

Bar plots and box plots were created with GraphPad Prism 9.3.1 software. Significance determined by ANOVA, Tukey's analysis and student's t-test.

Results

The method for measuring eNOS activity in 2D cell culture was first optimized and validated using isotope-labeled arginine, LC-MS/MS analysis, and staining using DAF. Next, the method was also optimized for the 3D microvessels-on-chip model, and finally, the eNOS activity measured for the 2D and 3D microvessels-on-chip model.

Tracer-based measurement of eNOS-dependent arginine to citrulline conversion - Marker metabolites that reflect eNOS activity

The targeted analysis of isotope-labeled L-arginine and its downstream metabolites, L-citrulline and L-ornithine, was conducted using the sample preparation method involving AccQ-Tag derivatization. The metabolic pathway of L-arginine metabolism and its conversion to downstream metabolites, as illustrated in (**Fig. 1A**), was the focal point of our analysis. We optimized the method by analyzing potential isotopologues of these marker metabolites in the cell system (**Supplementary Table. 1**).

After treating the HCAECs with isotope labelled L-arginine, we analyzed the resulting samples to identify peaks representing a series of isotopomeric citrulline, arginine and ornithine in the reconstructed ion chromatograms (**Fig. 1B**). Arginine was detected with M+10 (representing $^{13}\text{C}_6$, $^{15}\text{N}_4$ labeling) as a primary isotopologue, accounting for over 60% in all samples. Citrulline was detected with M+9 (representing $^{13}\text{C}_6$, $^{15}\text{N}_3$) as the primary isotopologue, produced by losing one nitrogen. Ornithine was detected with M+7 (representing $^{13}\text{C}_5$, $^{15}\text{N}_2$), resulting from the loss of one carbon and two nitrogen atoms from arginine. In the subsequent analysis, $^{13}\text{C},^{15}\text{N}$ -arginine (M+10), $^{13}\text{C},^{15}\text{N}$ -citrulline (M+9) and $^{13}\text{C},^{15}\text{N}$ -ornithine (M+7) were selected as biomarkers for further investigation. The measurements of blank samples (only media) showed no background interference in isotope-labeled citrulline or ornithine peaks (results not shown).

To optimize the incubation time, we considered the effects observed with stimulatory and inhibitory compounds. We utilized the detected isotopologues to verify the uptake of $^{13}\text{C}_6$, $^{15}\text{N}_4$ -L-arginine and reconstruct the metabolic pathways controlled by eNOS and

arginase in HCAECs. This analysis encompassed four conditions: 1) control, 2) treatment with the stimulatory compound VEGF, known for inducing NO release from endothelial cells[45]; 3) treatment with the eNOS inhibitory compound L-NAME [46,47]; and 4) treatment with the arginase enzyme inhibitor BEC [48]. The pathway and resulting metabolite expression for each treatment are depicted in Figure 2 (Fig. 2 A-C).




Figure 1. Tracer-based Nitric Oxide (NO) metabolomics study. (A) Metabolic pathway of L-arginine and a few metabolites involved in other functions. Three marker metabolites (in bold) were analyzed based on stimulated and inhibited conditions of the respective enzymes eNOS and arginase. (B) Representative ion chromatograms of metabolite isotopologues detected in HCAECs sample obtained after cells were incubated with 150 μ M of, $^{13}\text{C}_6$ $^{15}\text{N}_4$ L-arginine.

The optimization process led us to select a 12-hour incubation time after the introduction of tracers. We observed lower labeling incorporation at 3 and 6 hours, as indicated by the ratio of citrulline+9/arginine+10 and ornithine+7/arginine+10 (**Supplementary Fig. 1**). This rate of label incorporation could be influenced by the exchange of intracellular and extracellular (in medium) metabolites. Thus, we opted for a 12-hour treatment to see a maximal transfer of ^{13}C and ^{15}N atoms. The calculated isotopologue fractions after 12 hours of incubation time show the utilization of labelled arginine converted into maximum transition state of labelled citrulline (M+9) and ornithine (M+7) in extracellular samples.

In intracellular samples, the degree of labelling (citrulline (M+9) and ornithine (M+7) compared to the unlabeled isotopologue) was lower than in the medium. (**Supplementary Fig. 2A & 2B**). While the precise reason for this remains unclear, the suppression of citrulline generation by L-NAME is evident in both media and cells. Additionally, the hindrance of ornithine production by BEC is also distinctly observed in both media and cells. Indeed, the collective impact (notably, the isotopologue fraction of labeled citrulline (M+9)) is more pronounced in the medium.

Extracellular and intracellular measurement of Isotopomeric compounds

In order to comprehensively understand the effects of stimulatory and inhibitory compound treatments and to evaluate cellular metabolism, we conducted measurements of marker metabolites both intracellularly and extracellularly in a 2D cell culture platform. HCAECs were treated with eNOS stimulator (VEGF), eNOS inhibitor (L-NAME) and arginase inhibitor (BEC) in conditioned media containing $^{13}\text{C}_6$, $^{15}\text{N}_4$ L-arginine for 12 hours. Subsequently, both extracellular (media) and intracellular (cell)

samples were analyzed with LC-MS/MS. The targeted metabolic routes for individual treatments are illustrated in (Fig. 2 A-C).




Figure 2. Measurement of isotope labelled extracellular (media) and intracellular (cells) marker metabolites involved in NO mechanism in 2D model. A) Schematic representation of

NO pathway upon treatment of A) VEGF – eNOS stimulation B) L-NAME - eNOS inhibition and C) BEC – arginase inhibition. Highlighted and non-highlighted paths represent activation and inhibition conditions. Measurement of metabolites in media and cells (D) $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine and its (E) Pearson correlation (F) $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline and its (G) Pearson correlation (H) $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine and its (I) Pearson correlation. All error bars represent SD and mean, each dot represents technical replicates, $n=3$. Significance determined by student t-test of treated group versus control group. *, $P<0.05$; **, $P<0.01$; ***, $P<0.001$; ****, $P<0.0001$.

$^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine was present in a high amount in the medium and was also high in the cell. VEGF, L-NAME and BEC did not change the labelled arginine level significantly in media or cells, and that is not unexpected due to the high level as substrate (**Fig. 2D**), and as the levels were rather constant in cell and medium for the various conditions, no significant correlation was found for values of $^{13}\text{C}_6, ^{15}\text{N}_4$ L-Arginine (Pearson correlation coefficient P value = 0.6, $R^2 = 0.01$) (**Fig. 2E**). The peak intensity of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline in the medium was increased in VEGF when compared to control but no statistical difference seen in cells (**Fig. 2F**).

The eNOS inhibition with L-NAME treatment shows significantly lower $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline in cells and media, while with arginase inhibition, the levels were not significantly changed. Overall, our results show that there is a significant positive correlation between media and cells for $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline (Pearson correlation coefficient, $p = 0.0003$, $R^2 = 0.7$) (**Fig. 2G**). The $^{13}\text{C}_5, ^{15}\text{N}_2$ L-Ornithine levels were not significantly affected by VEGF and L-NAME treatments, in contrast to the condition where a specific inhibition of the arginase enzyme with BEC treatment was added, resulting in decreased ornithine levels (**Fig. 2H**). When we measured $^{13}\text{C}_5, ^{15}\text{N}_2$ L-Ornithine in media and cells, a significant positive correlation with p value = 0.0001, $R^2 = 0.7$ was observed (**Fig. 2I**).

Analysis of metabolic ratios to understand NO metabolic flux

Employing the tracer-based extracellular measurement method highlighted earlier, our emphasis was on ratios indicative of metabolic fluxes. We conducted inquiries involving

both individual and combined treatments of endothelial cells with compounds that stimulate and inhibit eNOS and arginase enzymes.

Under eNOS stimulation conditions (VEGF, Pathway **Fig. 2A**) the expected outcome is a maximized production of citrulline compared to conditions involving arginase and eNOS inhibition (Pathway **Fig. 2B & 2C**). The ratio $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline/ $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine was found to be significantly higher in the VEGF treatments, indicating a greater utilization of arginine for citrulline conversion (**Fig. 3A**). The $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline/ $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine ratio serves as an indicator of the balance in the metabolic pathway associated with arginase and eNOS activities. Our results show a significant increase is observed in arginase inhibition conditions (BEC, and VEGF+BEC) (**Fig. 3B**). The inhibition of eNOS by L-NAME treatments (L-NAME, and VEGF+L-NAME) (**Fig. 3B**), led to lower levels of citrulline and $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline/ $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine ratio indicating that the eNOS inhibition was selective. The $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine/ $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine ratio, analyzed to confirm the utilization of arginine to ornithine conversion, showed lower expression in all arginase inhibition (BEC) conditions compared to other treatments (**Fig. 3C**).




Figure 3. Measurement of extracellular labelled metabolites in 2D platform with the treatment of stimulators and inhibitors in an individual and combinational treatments. (A) Ratio of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine (B) ratio of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine and (C) ratio of $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine / $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine. All error bars represent SD and mean, each dot represents biological replicates. Significance determined by ANOVA and Tukey's multiple comparison test. ns = not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

Validation of eNOS activity using NO specific DAF-2DA staining

To determine if citrulline production can serve as an estimate of eNOS activity, we compared the peak intensities of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline with another measure of eNOS activity - Diaminofluorescein-2 diacetate (DAF-2DA) fluorescence staining for detecting intracellular NO. When DAF-2DA is taken up by cells, cytoplasmic esterase cleaves the acetate groups to generate DAF-2 which can readily react with dinitrogen trioxide (N_2O_3), an oxidation product of NO, to generate highly fluorescent triazolo fluorescein (DAF-2T) (Fig. 4).




Figure 4. NO specific DAF- 2 DA fluorescent stain on HCAECs.

(A) Microscopic images of HCAECs using fluorescent NO stain DAF-2DA in all treatments; eNOS stimulator (VEGF), inhibitor (L-NAME) and arginase inhibitor (BEC). (B) Intensity of the fluorescent stain was calculated by grey scale measurement using ImageJ software; $n=10$. (C) Spearman correlation of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline and DAF-2T fluorescence intensity. Significance determined by student t-test. ns = not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

This experiment was conducted in the 2D platform (48 wells cell culture plate) under the same conditions used for metabolic read out-as described in the preceding section. DAF-2T fluorescence intensity is significantly higher in VEGF and BEC conditions, and lower intensity was observed in the L-NAME condition (**Fig. 4A & 4B**). This outcome aligns with observations indicating that VEGF stimulation leads to a simultaneous increase in $^{13}\text{C}_6$ $^{15}\text{N}_3$ L-citrulline peak intensity (**Fig. 2F media**) and the augmentation of DAF-2T signals in HCAECs (**Fig. 4B**). To compare the relation between NO level and citrulline production, we performed a correlation analysis. Overall, the statistical analyses of the data indicate significant correlation between DAF-2T fluorescent intensity vs. $^{13}\text{C}_6$ $^{15}\text{N}_3$ L-citrulline peak intensity (Spearman correlation coefficient, $p = 0.007$, $R^2 = 0.53$) indicating that $^{13}\text{C}_6$ $^{15}\text{N}_3$ L-citrulline production and NO production from 2D model is significantly linked to the eNOS controlled treatments (**Fig. 4C**). Results from the DAF-2DA stain in the 3D model were inconclusive due to the presence of the collagen matrix. This matrix caused high background staining, making it difficult to distinguish the specific signal from the endothelial cells. Hence the results were not shown.

Comparison of mechanosensitive Klf2 gene in static (2D) and flow mediated (3D) cell culture models

To investigate the importance of shear stress on eNOS activation at the gene and metabolic level, we used a 3D culture model utilizing a novel setup – the MIMETAS 2-lane rerouted OrganoPlate (**Fig. 5A**). The commercially available MIMETAS 2-lane OrganoPlate's chip design was altered (rerouted) by connecting the route of windows 1 and 4 (**Fig. 5B**), extending the surface area for more cell growth. More important, this design is suitable to connect our microfluidic pump to create a flow, in contrast to the commercial MIMETAS OrganoPlate, where such a connected route is not present, as flow is applied using the rocker platform that generates bidirectional flow [29]. The microchannels in the OrganoPlate for gel and perfusion (blue -1 and pink-2 channel) are illustrated in **Fig. 5C**.




Figure 5. Representation of our 3D blood vessel model and comparison of NO marker metabolites in 2D and 3D platforms.

(A-C) Illustration of re-routed OrganoPlate's single chip design; Every microfluidic chip structure is positioned underneath 4 adjacent wells. Each microfluidic chip consists of two channels: The

blue color represents a ‘perfusion’ channel and pink color represents a ‘gel’ channel (ECM) separated by a phase guide (*). Every first well (1) and fourth well (4) is positioned on top of the inlet and outlet of the perfusion channel, while every second well (2) is for the gel channel and every third well (3) is used for imaging and observation of the experiment. (D) Immunostaining of HCAECs in a chip. After 48 hours of cell seeding, confluent vessels of HCAECs were immunostained with V-Cadherin, Actin and DAPI. (E) Image of a microfluidic pump with the two metal tubes attached to the inlet and outlet of the rerouted OrganoPlate to carry fluid and create unidirectional flow. (F) measurement of KLF2 gene expression of cell samples and (G) Measurement of extracellular metabolite’s ratio - $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine, $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine, $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine / $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine, all obtained from 2D static (black bars), 3D rocker platform (bidirectional flow model – blue bars) & the rerouted OrganoPlate with microfluidic perfusion pump operated with different shear stresses (unidirectional flow model) 0.3 dyne/cm² – (brown bars), 5 dyne/cm² - (green bars). Data for RT-PCR are presented as mean and s.e.m; n = 3. Metabolic data significance was determined by one way ANOVA multiple comparison test. *, P<0.05; **, P<0.01; ***, P <0.001; ****, P<0.0001.

The microchannels in the OrganoPlate were coated with gelatin, preventing HCAECs from growing on glass and enabling them to form stable microvessels which was checked by immunostaining (**Fig. 5D**). The rerouted OrganoPlate was connected to the microfluidic pump as shown in **Fig. 5E**.

For this study, we utilized three different cell culture models: a) the 2D model in which cells were grown in a static conventional culture, b) a bidirectional flow model – MIMETAS 2-lane OrganoPlate with normal chip design subjected to flow using an interval rocker device [29] and c) a unidirectional flow model - the rerouted plate with microfluidic pump set to two different dyne stresses, namely 0.3, and 5.0 dyne/cm². From these platforms, HCAECs were collected, and RNA was isolated at 12 and 24 hours. The isolated RNA was transcribed to cDNA with the respective primers and quantified using the RT-PCR technique. The results of the 12-hour incubation reveal a significant upregulation of the Klf2 gene in microvessels perfused with the interval rocker and with the microfluidic pump (5 dyne/cm²).

Furthermore, the results of the 24-hour incubation demonstrate that cells subjected to perfusion with interval rocker platform exhibit a significant upregulation of the Klf2 gene

compared to cells in the 2D well plate, and microvessels perfused with the pump may exhibit a further increase in Klf2 gene expression (**Fig. 5F**).

Comparison of NO marker metabolites in static (2D) and flow mediated (3D) cell culture models

Metabolic analysis was performed in the samples obtained from the above-mentioned models (in Section 3.2 and 3.3), and ratios of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-Citrulline, $^{13}\text{C}_5, ^{15}\text{N}_2$ L-Ornithine and $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine were evaluated. The ratio of $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline/ $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine and $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine / $^{13}\text{C}_6, ^{15}\text{N}_4$ L-arginine are higher for 2D than 3D experiments, indicating that the total eNOS and arginase activity is higher in 2D than 3D. More relevant, the ratio of labelled citrulline and ornithine is higher for 3D than 2D indicating that the ratio of eNOS activity to arginase activity is higher for 3D than 2D, which is expected due to the flow present in 3D. (**Fig. 5G**).

The metabolic effects of VEGF, L-NAME and BEC treatments were comparable between 2D and 3D cultures for the above-mentioned ratios (**Supplementary Fig. 4 A- C**). However, the $^{13}\text{C}_6, ^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5, ^{15}\text{N}_2$ L-ornithine ratio showed a significant increase in all the 3D models when eNOS was stimulated by VEGF but was not significantly higher in 2D culture compared to control (**Supplementary Fig. 4A**).

Discussion

The purpose of this study was to understand endothelial NO production from a metabolic standpoint. We examined isotope-labeled arginine-based NO metabolic modifications by employing specific stimulant and inhibitory compounds targeting eNOS and arginase enzymes. Our focus was on measuring the impact of adverse metabolic and inflammatory factors on NO synthesis in endothelial cells, and for this purpose, we developed a highly sensitive tracer-based method to quantify eNOS-dependent conversion of arginine to citrulline and ornithine.

Upon introducing the arginine isotope to the HCAECs, we optimized the time required for the conversion of isotope-labeled citrulline and ornithine. Through the optimization process, we determined that a 12-hour incubation period after tracer introduction yielded the most favorable results. Notably, lower labeling incorporation was observed at 3 and 6 hours, as evidenced by the citrulline+9/arginine+10 and ornithine+7/arginine+10 ratios (**Supplementary Fig. 1**).

The incorporation rate of labels may be impacted by the exchange of metabolites between intracellular and extracellular (in medium) environments. Consequently, we chose a 12-hour treatment to observe the maximal transfer of ^{13}C and ^{15}N atoms. The calculated isotopologue fractions following a 12-hour incubation period reveal the utilization of labeled arginine, leading to the maximum transition state of labeled citrulline (M+9) and ornithine (M+7) in extracellular samples. In intracellular samples, the degree of labelling (citrulline (M+9) and ornithine (M+7) compared to the unlabeled isotopologue) was lower than in the medium (**Supplementary Fig. 2A & 2B**).

Upon introducing the isotope labeled arginine to the HCAECs and when treated with stimulatory and inhibitory compounds, it can be inferred that discernible (relative, not absolute) variations in eNOS and arginase activities can be identified through the assessment of the M+9 isotopologue of citrulline and M+7 ornithine in the medium. Additionally, it is imperative to emphasize that when evaluating the impact of conditions on eNOS activity, a control experiment must be incorporated as a reference. Moreover, a notable abundance of the M+6 isotopologue in arginine is observed, attributed to its conversion through an alternative pathway. It was concluded that the obtained labelled marker metabolites were relatively high after 12 hours in the medium, therefore, further analyses were performed on medium samples produced after 12 hours of incubation.

The response of eNOS stimulation using VEGF was to enhance the NO production through the activation of tyrosine kinase activity, resulting in the phosphorylation of intracellular domains. This activation increases calcium levels, facilitates binding with calmodulin (CaM), enhances eNOS phosphorylation, and ultimately leads to increase NO production [49–52]. The mechanism via receptor activation is depicted in

Supplementary Fig. 3. Our results indicate that eNOS activation leads to increased citrulline, consistent with its role as a co-product of NO production.

Earlier studies have reported BEC as a classical competitive inhibitor of arginase II at pH 7.5 with a dissociation constant (K_i) describing the binding affinity between the inhibitor and the enzyme as 0.25 and 0.31 μM [53]. Therefore, both citrulline and ornithine, upon stimulatory and inhibitory compound exposures, exhibited similar effects between media and cells. In general, most of the *in vitro* analyses measured NO metabolites only as intracellular levels [54,55]. In our study, we showed that the obtained promising results showed extracellular and intracellular expressions are positively correlated and this approach is helpful for fluxomics studies.

Ratios of NO metabolites can function as valuable indicators of diseased conditions and considered as useful markers in cardiovascular diseases, offering insights into the underlying biological mechanisms and disrupted pathways associated with the disease state. In particular, the tracer-based approach allowed us to gain a comprehensive understanding of how these compounds, both individually and in combination, influence the metabolic pathways associated with endothelial dysfunction. The ratio of unlabeled citrulline to arginine has been extensively examined in diabetes condition [56] and in children with chronic kidney disease (CKD) and abnormal cardiac blood pressure conditions, reporting a higher citrulline-to-arginine (cit-arg) ratio in plasma [57] but a lower ratio reported in urine [58]. In our study using stable isotope ratios instead of unlabeled ratios, we were able to overcome the difficulties resulting from the large volume of media used compared to the cell content and clearly link the arginine substrate to downstream products. The higher ratio resulting from the BEC inhibition suggests that arginase inhibition could be a potential target for recovering NO or citrulline production in diseased conditions. Our data supports the idea that the arginase inhibition recovers citrulline levels better than the stimulated condition with more arginine availability [59]. Furthermore, the combinational exposure experiments provide insights to the metabolic alterations in a controlled fashion. For instance, in VEGF+BEC condition, production of $^{13}\text{C}_6$, $^{15}\text{N}_3$ L-citrulline was directly from arginine rather than from ornithine as the pathway is blocked by the arginase inhibitor BEC. Such information is valuable for comparing the

underlying mechanisms of disease and identifying potential targets for therapeutic interventions.

Measurement of DAF-2T, the NO specific stain, revealed higher fluorescent intensity for both VEGF and BEC conditions which indicates an enhancement of NO production with VEGF addition, as previously demonstrated in HUVECs cells [60]. Similarly, increased DAF-2T intensity in arginase inhibition indicated the restoration of NO production, consistent with what was reported earlier in human aortic endothelial cells (HAECs) [61]. After successful use of the DAF-2T staining in the 2D HACEC model, we evaluated the staining in the 3D microvessels model. However direct staining was not successful, with the major challenge that the dye showed a too strong background signal when reacting to the collagen which was used as the extracellular matrix in the 3D microvessels model (results not shown). Therefore, to confirm the impact of flow that creates change in isotope labeled citrulline peak levels in 3D model, the flow-sensitive gene expression was measured.

Endothelial response to fluid flow is a crucial factor in vascular regulatory function. Flow-mediated eNOS activity in endothelium releases the endogenous nitro vasodilator, NO [17,62,63]. We validated the functionality of our microfluidic pump, using quantitative RT-PCR to measure the impact of shear stress on the shear-dependent transcription of the Klf2 gene [64] which also plays an important role in endothelial function, anti-inflammatory, anti-thrombotic and angiogenesis [63,65]. This indicates that our flow model induces substantial upregulation of the shear dependent gene – Klf2, highlighting the effectiveness of our 3D model in providing proper flow conditions to cells and allowing variations in shear stress compared to 2D.

The advantage of comparing ratios of 2D and 3D model rather than comparing individual metabolites is that ratios eliminate the need for additional normalization methods such as cell count or protein levels for some (but not all) comparisons. The ratio of $^{13}\text{C}_6,^{15}\text{N}_3$ L-citrulline/ $^{13}\text{C}_6,^{15}\text{N}_4$ L-arginine and $^{13}\text{C}_5,^{15}\text{N}_2$ L-ornithine / $^{13}\text{C}_6,^{15}\text{N}_4$ L-arginine are higher for 2D than 3D experiments, indicating that the total eNOS and arginase activity is higher in 2D than 3D, but this may be due to the higher number of cells in the 2D model. The

influence of flow is evident in the $^{13}\text{C}_6,^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5,^{15}\text{N}_2$ L-ornithine ratio, indicating that flow “regulates” metabolic expression by enhancing eNOS activity when compared to the static 2D model. This might be because the cells in 2D model undergo stress due to the stiff base substrate and a static culture method, which mimics the status of endothelial dysfunction. These findings support the hypothesis of a relative arginase hyperactivity leading to endothelial dysfunction (ED) in mice [66] and in diabetes patients with ED condition [67]. Furthermore, the loss of fluid flow combined with a mTOR-based regulatory mechanism to balance eNOS and arginase II expression results in elevated $^{13}\text{C}_5,^{15}\text{N}_2$ L-ornithine and decreased $^{13}\text{C}_6,^{15}\text{N}_3$ L-citrulline levels, which indicates ED, consistent with what was reported in these studies [68,69].

Flow induced increases in NO production compared to static culture was previously reported [70]. Our results also show similar findings that in a 3D flow model, the fluid shear stress induces the signal of PECAM-1 that acts through adaptor molecules such as phosphatidylinositol-3-kinase (PI3K), which then activates eNOS, mTOR and the transcription factor Klf2 to regulate the functional genes [63]. Therefore, a lower $^{13}\text{C}_6,^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5,^{15}\text{N}_2$ L-ornithine ratio in 2D static culture mimics more of endothelial dysfunction conditions. With the microfluidic pump, the flow can be controlled; for the $^{13}\text{C}_6,^{15}\text{N}_3$ L-citrulline / $^{13}\text{C}_5,^{15}\text{N}_2$ L-ornithine ratio, the data for the rocker platform and microfluidic platform using a shear stress of 5 dyne/cm² were not statistically significant.

Conclusion

We developed a stable isotope LC-MS/MS based assay to determine eNOS activity and verified this method by showing that indeed eNOS expression was present with reference staining (DAF-2D), and inhibitors of eNOS and arginase did show the expected effect. We then used this method to measure eNOS activity of HCAECs in 2D culture, and in a 3D microvessels model with flow through the microvessels. We used a bidirectional flow and used a set-up with a unidirectional flow system generated by a microfluidic pump. Compared to 2D culture, the 3D model has higher eNOS activity. Additionally, our optimized MS method proves to be ideal for measuring NO marker metabolites at both

extracellular and intracellular levels, providing valuable insights into metabolic flux. Actually, the method can be used to determine the effect of medium or plasma perfused through the microvessels on eNOS activity by measuring the conversion of labelled arginine to citrulline in medium (extracellular), which is much more straightforward than extracting the endothelial cell content. This eNOS activity assay has advantages over fluorescent probes which may have background from extracellular matrix and has the potential to be fast and high throughput as lysis of cells is not necessary and could be conducted at several time points throughout an experiment.

In future studies, this method could be applied to assess the effect of patient's plasma on eNOS activity by perfusing patient plasma samples in the 3D models and analyzing the degree of pathological conditions and drug responses. Combining flux data with other omics data in future studies would offer a more comprehensive understanding of NO's vasodilatory effects in studying endothelial dysfunctions. Furthermore, enhancing the pump system with higher shear forces could be explored to apply to various endothelial cell types, emulating different micro vessel models. In conclusion, our validation of shear stress's impact on eNOS using our 3D cell culture model from a metabolic perspective is a novel approach to study endothelial (dys)function.

Conflict of interest

T. Hankemeier is a shareholder in Mimetas B.V. All other authors declare no competing interests.

Data availability statement

The data that support the findings of this study are available in the Materials and Methods, Results, and Supplementary Material of this article. Additional data will be provided upon request.

Author contributions

K. Pandian, Conceptualization, Investigation, Methodology, Writing - original draft;
 L. Huang, Methodology – mass spectrometry method, Writing – review and editing;
 A. Junaid, Methodology – microfluidic pump designing, Writing – review and editing;
 A. Harms, Writing – review and editing;
 A. Jan van Zonneveld and T. Hankemeier, Conceptualization, Resources, Supervision,
 Funding acquisition, Writing – review and editing.

Acknowledgements

Parts of these studies were supported by the Dutch Heart Foundation (CVON RECONNECT) and ZonMW (MKMD: 114022501) grants to T.H and A.J.V.Z. Part was supported by METABODELTA (Medical Delta program). This project has received funding from the European Union's Horizon 2020 research and innovation Programme LogicLab under the Marie Skłodowska-Curie grant agreement No 813920, and RECONNECT funded by the Dutch Heart Foundation No 2020B008.

References

- [1] Hickok, J.R. *et al.* (2013). Oxygen dependence of nitric oxide-mediated signaling. *Redox Biology*. <https://doi.org/10.1016/j.redox.2012.11.002>.
- [2] Bauer, P.M. *et al.* (2003). Compensatory Phosphorylation and Protein-Protein Interactions Revealed by Loss of Function and Gain of Function Mutants of Multiple Serine Phosphorylation Sites in Endothelial Nitric-oxide Synthase*. *Journal of Biological Chemistry*. <https://doi.org/10.1074/jbc.M211926200>.
- [3] Archer, S.L. *et al.* (1994). Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. *Proceedings of the National Academy of Sciences of the United States of America*. <https://doi.org/10.1073/pnas.91.16.7583>.
- [4] Russo, G. *et al.* (2002). Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. *Vascular Pharmacology*. [https://doi.org/10.1016/s1537-1891\(02\)00250-1](https://doi.org/10.1016/s1537-1891(02)00250-1).
- [5] Murad, F. (2004). Discovery of some of the biological effects of nitric oxide and its role in cell signaling. *Bioscience Reports*. <https://doi.org/10.1007/s10540-005-2741-8>.
- [6] Kingwell, B.A. (2000). Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease. *Clinical and Experimental Pharmacology & Physiology*. <https://doi.org/10.1046/j.1440-1681.2000.03232.x>.

- [7] Trochu, J.-N. *et al.* (2000). Role of Endothelium-Derived Nitric Oxide in the Regulation of Cardiac Oxygen Metabolism. *Circulation Research*. <https://doi.org/10.1161/01.RES.87.12.1108>.
- [8] Pechánová, O. *et al.* (2015). Cardiac NO signalling in the metabolic syndrome. *British Journal of Pharmacology*. <https://doi.org/10.1111/bph.12960>.
- [9] Feng, Q. and Hedner, T. (1990). Endothelium-derived relaxing factor (EDRF) and nitric oxide (NO). II. Physiology, pharmacology and pathophysiological implications. *Clinical Physiology (Oxford, England)*. <https://doi.org/10.1111/j.1475-097x.1990.tb00443.x>.
- [10] Flammer, A.J. and Lüscher, T.F. (2010). Human endothelial dysfunction: EDRFs. *Pflügers Archiv: European Journal of Physiology*. <https://doi.org/10.1007/s00424-010-0822-4>.
- [11] Bevers, L.M. *et al.* (2006). Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. *Hypertension (Dallas, Tex.: 1979)*. <https://doi.org/10.1161/01.HYP.0000196735.85398.0e>.
- [12] Chen, C.-A. *et al.* (2010). S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. *Nature*. <https://doi.org/10.1038/nature09599>.
- [13] De Pascali, F. *et al.* (2014). Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation. *Biochemistry*. <https://doi.org/10.1021/bi500076r>.
- [14] McNeill, E. and Channon, K.M. (2012). The role of tetrahydrobiopterin in inflammation and cardiovascular disease. *Thrombosis and Haemostasis*. <https://doi.org/10.1160/TH12-06-0424>.
- [15] Wu, F. *et al.* (2014). Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury. *American Journal of Physiology. Lung Cellular and Molecular Physiology*. <https://doi.org/10.1152/ajplung.00063.2014>.
- [16] Yang, Y.-M. *et al.* (2009). eNOS uncoupling and endothelial dysfunction in aged vessels. *American Journal of Physiology - Heart and Circulatory Physiology*. <https://doi.org/10.1152/ajpheart.00230.2009>.
- [17] Cabral, P.D. *et al.* (2010). Shear stress increases nitric oxide production in thick ascending limbs. *American Journal of Physiology-Renal Physiology*. <https://doi.org/10.1152/ajprenal.00112.2010>.
- [18] Tanaka, K. *et al.* (2021). Early events in endothelial flow sensing. *Cytoskeleton*. <https://doi.org/10.1002/cm.21652>.
- [19] Corson, M.A. *et al.* (1996). Phosphorylation of Endothelial Nitric Oxide Synthase in Response to Fluid Shear Stress. *Circulation Research*. <https://doi.org/10.1161/01.RES.79.5.984>.
- [20] Fleming, I. *et al.* (2005). Role of PECAM-1 in the shear-stress-induced activation of Akt and the endothelial nitric oxide synthase (eNOS) in endothelial cells. *Journal of Cell Science*. <https://doi.org/10.1242/jcs.02541>.
- [21] Nagel, T. *et al.* (1999). Vascular Endothelial Cells Respond to Spatial Gradients in Fluid Shear Stress by Enhanced Activation of Transcription Factors. *Arteriosclerosis, Thrombosis, and Vascular Biology*. <https://doi.org/10.1161/01.ATV.19.8.1825>.

- [22] Tovar-Lopez, F. *et al.* (2019). A Microfluidic System for Studying the Effects of Disturbed Flow on Endothelial Cells. *Frontiers in Bioengineering and Biotechnology*.
- [23] Williams, D. *et al.* (2021). Stable Flow-induced Expression of KLK10 Inhibits Endothelial Inflammation and Atherosclerosis. *bioRxiv*. <https://doi.org/10.1101/2021.08.10.455857>.
- [24] Barak, O.F. *et al.* (2017). Disturbed blood flow worsens endothelial dysfunction in moderate-severe chronic obstructive pulmonary disease. *Scientific Reports*. <https://doi.org/10.1038/s41598-017-17249-6>.
- [25] Junaid, A. *et al.* (2020). Metabolic response of blood vessels to TNF α . *eLife*. <https://doi.org/10.7554/eLife.54754>.
- [26] Cabrera, A.P. *et al.* (2022). Increased cell stiffness contributes to complement-mediated injury of choroidal endothelial cells in a monkey model of early age-related macular degeneration. *The Journal of Pathology*. <https://doi.org/10.1002/path.5892>.
- [27] <https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.305720>.
- [28] Schaefer, A. and Hordijk, P.L. (2015). Cell-stiffness-induced mechanosignaling – a key driver of leukocyte transendothelial migration. *Journal of Cell Science*. <https://doi.org/10.1242/jcs.163055>.
- [29] van Duinen, V. *et al.* (2017). 96 perfusable blood vessels to study vascular permeability in vitro. *Scientific Reports*. <https://doi.org/10.1038/s41598-017-14716-y>.
- [30] Taylor, D.R. *et al.* (2006). Exhaled nitric oxide measurements: clinical application and interpretation. *Thorax*. <https://doi.org/10.1136/thx.2005.056093>.
- [31] Sandrini, A. *et al.* (2010). Fractional exhaled nitric oxide in asthma: an update. *Respirology*. <https://doi.org/10.1111/j.1440-1843.2009.01616.x>.
- [32] Vidanapathirana, A.K. *et al.* (2019). A Novel Ruthenium-based Molecular Sensor to Detect Endothelial Nitric Oxide. *Scientific Reports*. <https://doi.org/10.1038/s41598-019-39123-3>.
- [33] Hunter, R.A. and Schoenfisch, M.H. (2015). S-Nitrosothiol analysis via photolysis and amperometric nitric oxide detection in a microfluidic device. *Analytical Chemistry*. <https://doi.org/10.1021/ac503220z>.
- [34] Moon, J. *et al.* (2016). Dual Electrochemical Microsensor for Real-Time Simultaneous Monitoring of Nitric Oxide and Potassium Ion Changes in a Rat Brain during Spontaneous Neocortical Epileptic Seizure. *Analytical Chemistry*. <https://doi.org/10.1021/acs.analchem.6b02396>.
- [35] Chokkathukalam, A. *et al.* (2014). Stable isotope-labeling studies in metabolomics: new insights into structure and dynamics of metabolic networks. *Bioanalysis*. <https://doi.org/10.4155/bio.13.348>.
- [36] Paul Lee, W.-N. *et al.* (2010). Tracer-based metabolomics: Concepts and practices. *Clinical Biochemistry*. <https://doi.org/10.1016/j.clinbiochem.2010.07.027>.
- [37] Siervo, M. *et al.* (2011). Measurement of in vivo nitric oxide synthesis in humans using stable isotopic methods: a systematic review. *Free Radical Biology and Medicine*. <https://doi.org/10.1016/j.freeradbiomed.2011.05.032>.

- [38] Gambardella, J. *et al.* (2020). Arginine and Endothelial Function. *Biomedicines*. <https://doi.org/10.3390/biomedicines8080277>.
- [39] Shatanawi, A. *et al.* (2020). L-Citrulline Supplementation Increases Plasma Nitric Oxide Levels and Reduces Arginase Activity in Patients With Type 2 Diabetes. *Frontiers in Pharmacology*.
- [40] Figueroa, A. *et al.* (2020). L-Citrulline Supports Vascular and Muscular Benefits of Exercise Training in Older Adults. *Exercise and Sport Sciences Reviews*. <https://doi.org/10.1249/JES.0000000000000223>.
- [41] Kucharzewska, P. *et al.* (2010). Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. *Experimental Cell Research*. <https://doi.org/10.1016/j.yexcr.2010.05.033>.
- [42] Shin, B.S. *et al.* (2015). Estimation of nitric oxide synthase activity via LC-MS/MS determination of 15N3-citrulline in biological samples. *Rapid communications in mass spectrometry : RCM*. <https://doi.org/10.1002/rcm.7124>.
- [43] Junaid, A. (2020). *Microengineered human blood vessels for next generation drug discovery*, Leiden University Dissertation. <https://hdl.handle.net/1887/138650>.
- [44] Noga, M.J. *et al.* (2012). Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. *Metabolomics: Official Journal of the Metabolomic Society*. <https://doi.org/10.1007/s11306-011-0306-3>.
- [45] Feliers, D. *et al.* (2005). VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. *Kidney International*. <https://doi.org/10.1111/j.1523-1755.2005.00575.x>.
- [46] Rees, D.D. *et al.* (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. *British Journal of Pharmacology*. <https://doi.org/10.1111/j.1476-5381.1990.tb14151.x>.
- [47] Silva, F.C. da *et al.* (2022). Endothelial dysfunction due to the inhibition of the synthesis of nitric oxide: Proposal and characterization of an in vitro cellular model. *Frontiers in Physiology*.
- [48] Caldwell, R.B. *et al.* (2015). Arginase: an old enzyme with new tricks. *Trends in pharmacological sciences*. <https://doi.org/10.1016/j.tips.2015.03.006>.
- [49] Grover, T.R. *et al.* (2002). Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus. *Pediatric Research*. <https://doi.org/10.1203/00006450-200212000-00016>.
- [50] Pandey, A.K. *et al.* (2018). Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. *Hypertension (Dallas, Tex.: 1979)*. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10271>.
- [51] Cazzaniga, A. *et al.* (2018). The Contribution of EDF1 to PPAR γ Transcriptional Activation in VEGF-Treated Human Endothelial Cells. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms19071830>.

- [52] Gélinas, D.S. *et al.* (2002). Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathways. *British Journal of Pharmacology*. <https://doi.org/10.1038/sj.bjp.0704956>.
- [53] Colleluori, D.M. and Ash, D.E. (2001). Classical and Slow-Binding Inhibitors of Human Type II Arginase. *Biochemistry*. <https://doi.org/10.1021/bi010783g>.
- [54] Hecker, M. *et al.* (1990). The Metabolism of L-Arginine and Its Significance for the Biosynthesis of Endothelium-Derived Relaxing Factor: Cultured Endothelial Cells Recycle L-Citrulline to L-Arginine. *Proceedings of the National Academy of Sciences of the United States of America*.
- [55] Tsuboi, T. *et al.* (2018). Administration of L-arginine plus L-citrulline or L-citrulline alone successfully retarded endothelial senescence. *PLOS ONE*. <https://doi.org/10.1371/journal.pone.0192252>.
- [56] Molnos, S. *et al.* (2018). Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. *Diabetologia*. <https://doi.org/10.1007/s00125-017-4436-7>.
- [57] Lin, Y.-J. *et al.* (2013). High citrulline-to-arginine ratio associated with blood pressure abnormalities in children with early chronic kidney disease. *Circulation Journal: Official Journal of the Japanese Circulation Society*. <https://doi.org/10.1253/circj.cj-12-0602>.
- [58] Lin, I.-C. *et al.* (2016). Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiffness in childhood chronic kidney disease. *Journal of the American Society of Hypertension: JASH*. <https://doi.org/10.1016/j.jash.2015.11.008>.
- [59] Shatanawi, A. and Momani, M.S. (2018). Arginase inhibition improves vascular function and restores NO production in diabetic conditions. *The FASEB Journal*. https://doi.org/10.1096/fasebj.2018.32.1_supplement.569.7.
- [60] Jo, H. *et al.* (2017). Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. *BMB Reports*. <https://doi.org/10.5483/BMBRep.2017.50.7.085>.
- [61] Ryoo, S. *et al.* (2008). Endothelial Arginase II. *Circulation Research*. <https://doi.org/10.1161/CIRCRESAHA.107.169573>.
- [62] Cooke, J.P. *et al.* (1991). Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. *The Journal of Clinical Investigation*. <https://doi.org/10.1172/JCI115481>.
- [63] Zhou, J. *et al.* (2014). Shear stress-initiated signaling and its regulation of endothelial function. *Arteriosclerosis, Thrombosis, and Vascular Biology*. <https://doi.org/10.1161/ATVBAHA.114.303422>.
- [64] Wang, N. *et al.* (2006). Shear stress regulation of Krüppel-like factor 2 expression is flow pattern-specific. *Biochemical and Biophysical Research Communications*. <https://doi.org/10.1016/j.bbrc.2006.01.089>.
- [65] Turpaev, K.T. (2020). Transcription Factor KLF2 and Its Role in the Regulation of Inflammatory Processes. *Biochemistry (Moscow)*.
- [66] Vaisman, B.L. *et al.* (2012). Selective Endothelial Overexpression of Arginase II Induces Endothelial Dysfunction and Hypertension and Enhances Atherosclerosis in Mice. *PLOS ONE*. <https://doi.org/10.1371/journal.pone.0039487>.


[67] Kövamees, O. *et al.* (2016). Amino acid metabolism reflecting arginase activity is increased in patients with type 2 diabetes and associated with endothelial dysfunction. *Diabetes & Vascular Disease Research*. <https://doi.org/10.1177/1479164116643916>.

[68] Decker, B. and Pumiglia, K. (2018). mTORc1 activity is necessary and sufficient for phosphorylation of eNOS1177. *Physiological Reports*. <https://doi.org/10.14814/phy2.13733>.

[69] Mammedova, J.T. *et al.* (2021). The Mechanisms of L-Arginine Metabolism Disorder in Endothelial Cells. *Biochemistry. Biokhimiia*. <https://doi.org/10.1134/S0006297921020036>.


[70] Noris, M. *et al.* (1995). Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. *Circulation Research*. <https://doi.org/10.1161/01.RES.76.4.536>.

Supplementary information




Supplementary Figure 1. Dosage study of stimulatory and inhibitory compounds and the extracellular measurement of marker metabolites.

(A & B) Ratios of $^{13}\text{C}_6$, $^{15}\text{N}_3$ L-Citrulline (Citrulline+9), $^{13}\text{C}_5$, $^{15}\text{N}_2$ L-Ornithine (L-Ornithine+7) and $^{13}\text{C}_6$, $^{15}\text{N}_4$ -L-arginine (L-Arginine+10) after the different dosage treatment of stimulator and inhibitors of eNOS and arginase enzyme on HCAECs at different incubation hours. Incubation hours represented in different colors. 3 hours – black bars; 6 – hours – brown bars; and 12 hours – blue bars. Significance is determined by one way ANOVA multiple comparison test. For Citrulline+9/Arginine+10 and for Ornithine+7/Arginine+10, overall significant difference was observed between 3, 6 and 12 hours with p value <0.0001.




Supplementary Figure 2. Isotopologue fractions of A) extracellular and B) intracellular of L-Arginine, L-Citrulline and L-Ornithine in stimulated and inhibited treatments and in control.



Supplementary Figure 3. Schematic representation of Vascular Endothelial Growth Factor (VEGF) stimulation over eNOS enzyme and NO production.

The external signals – agonist of nitric Oxide (NO) such as acetylcholine, ATP & ADP (adenosine triphosphate and diphosphate), VEGF etc., have specific receptor sites on the endothelial cell surface (Blue). When VEGF binds to the muscarinic receptor, it releases Calcium²⁺, a major factor that leads to the chain of events cause NO production. Once the receptors are stimulated by the agonists (VEGF) they act upon the endoplasmic reticulum (ER) by transferring the signal via SHB adaptor protein, PI3K (Phosphoinositide3 kinase) and protein kinases (Akt), increase Ca²⁺ level, that binds to the calmodulin protein and cause some conformational changes. In the presence of tetrahydrobiopterin (BH_4) and oxygen, it phosphorylates the enhance the eNOS phosphorylation. The activated eNOS will convert L-Arginine to L-Citrulline and co-product as Nitric Oxide (NO). Calcium level is balanced by the calcium potassium channel from the circulation. Illustration created BioRender.com, accessed on HV24G0AUF2, September 24, 2022.



Supplementary Figure 4. Measurement of extracellular marker metabolites in all platforms.

A) Comparison of metabolites ratio between 2D and 3D models A) Ratio $^{13}C_6, ^{15}N_3$ L-Citrulline / $^{13}C_5, ^{15}N_2$ L-Ornithine B) Ratio of $^{13}C_6, ^{15}N_3$ L-Citrulline / $^{13}C_6, ^{15}N_4$ L-arginine C) Ratio of $^{13}C_5, ^{15}N_2$ L-Ornithine / $^{13}C_6, ^{15}N_4$ L-arginine in stimulatory and inhibitory compounds treated samples from 2D static, 3D rocker platform (bidirectional flow model) & the rerouted OrganoPlate with microfluidic perfusion pump operated with different shear stresses (unidirectional flow model). Metabolic data significance was determined by one way ANOVA multiple comparison test. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

Supplementary table. 1. Modified MS acquisition method of 29 transition pairs of potential isotopologues of marker metabolites.

S.No	Metabolites name	Mass(Q1)	Mass(Q3)
1	L-Arginine [M+1]	346.170	171.000
2	L-Arginine [M+2]	347.170	171.000
3	L-Arginine [M+3]	348.170	171.000
4	L-Arginine [M+4]	349.170	171.000
5	L-Arginine [M+5]	350.170	171.000
6	L-Arginine [M+6]	351.170	171.000
7	L-Arginine [M+7]	352.170	171.000
8	L-Arginine [M+8]	353.170	171.000
9	L-Arginine [M+9]	354.170	171.000
10	L-Arginine [M+10]	355.170	171.000
11	L-Citrulline [M+1]	347.150	171.000
12	L-Citrulline [M+2]	348.150	171.000
13	L-Citrulline [M+3]	349.150	171.000
14	L-Citrulline [M+4]	350.150	171.000
15	L-Citrulline [M+5]	351.150	171.000
16	L-Citrulline [M+6]	352.150	171.000
17	L-Citrulline [M+7]	353.150	171.000
18	L-Citrulline [M+8]	354.150	171.000
19	L-Citrulline [M+9]	355.150	171.000
20	Ornithine [M+1]	237.600	171.000
21	Ornithine [M+2]	238.100	171.000
22	Ornithine [M+3]	238.600	171.000
23	Ornithine [M+4]	239.100	171.000
24	Ornithine [M+5]	239.600	171.000
25	Ornithine [M+6]	240.100	171.000
26	Ornithine [M+7]	240.600	171.000
27	L-Arginine	345.170	171.000
28	L-Citrulline	346.150	171.000
29	Ornithine	237.100	171.000